Lorus Therapeutics
Inc.
|
||||||||
Interim Consolidated Balance
Sheets
|
||||||||
As at
|
As at
|
|||||||
(amounts in
000's)
|
February 28,
2009
|
May 31,
2008
|
||||||
(Canadian
dollars)
|
(Unaudited)
|
|||||||
ASSETS
|
||||||||
Current
|
||||||||
Cash and cash
equivalents
|
$ | 5,644 | $ | 2,652 | ||||
Short term investments (note
7)
|
1,628 | 6,784 | ||||||
Prepaid expenses and other
assets
|
694 | 721 | ||||||
Amount held in escrow (note 1
(b))
|
- | 600 | ||||||
7,966 | 10,757 | |||||||
Long-term
|
||||||||
Fixed
assets
|
270 | 244 | ||||||
Goodwill
|
606 | 606 | ||||||
876 | 850 | |||||||
$ | 8,842 | $ | 11,607 | |||||
LIABILITIES
|
||||||||
Current
|
||||||||
Accounts
payable
|
$ | 312 | $ | 923 | ||||
Accrued
liabilities
|
1,300 | 1,194 | ||||||
Deferred gain on sale of shares
(note 1 (b))
|
- | 600 | ||||||
Secured convertible debentures
(note 8)
|
13,915 | - | ||||||
15,527 | 2,717 | |||||||
Long-term
|
||||||||
Secured convertible debentures
(note 8)
|
- | 12,742 | ||||||
SHAREHOLDERS'
DEFICIENCY
|
||||||||
Share Capital (note
5)
|
||||||||
Common
shares
|
162,111 | 158,743 | ||||||
Equity
portion of secured convertible debentures
|
3,814 | 3,814 | ||||||
Stock
options (note 6(c))
|
3,763 | 4,961 | ||||||
Contributed
surplus (note 5(e))
|
10,726 | 9,181 | ||||||
Warrants
|
417 | - | ||||||
Deficit accumulated during
development stage
|
(187,516 | ) | (180,551 | ) | ||||
(6,685 | ) | (3,852 | ) | |||||
$ | 8,842 | $ | 11,607 | |||||
See accompanying notes to the
unaudited consolidated interim financial statements
|
||||||||
Basis of Presentation Note
1
|
Lorus Therapeutics
Inc.
|
||||||||||||||||||||
Interim Consolidated Statements of
Loss and Deficit (unaudited)
|
||||||||||||||||||||
Period
|
||||||||||||||||||||
Three
|
Three
|
Nine
|
Nine
|
from
inception
|
||||||||||||||||
(amounts in 000's except for per
common share data)
|
months
ended
|
months
ended
|
months
ended
|
months
ended
|
Sept. 5, 1986
to
|
|||||||||||||||
(Canadian
dollars)
|
Feb. 28,
2009
|
Feb. 29,
2008
|
Feb. 28,
2009
|
Feb. 29,
2008
|
Feb. 28,
2009
|
|||||||||||||||
REVENUE (note
11)
|
$ | 64 | $ | 3 | $ | 106 | $ | 30 | $ | 962 | ||||||||||
EXPENSES
|
||||||||||||||||||||
Cost of
sales
|
- | 1 | - | 2 | 105 | |||||||||||||||
Research and
development
|
1,043 | 2,222 | 2,915 | 4,251 | 122,861 | |||||||||||||||
General and
administrative
|
822 | 863 | 2,583 | 2,702 | 57,794 | |||||||||||||||
Stock-based compensation (note
6)
|
111 | 217 | 347 | 529 | 8,319 | |||||||||||||||
Depreciation and amortization of
fixed assets
|
55 | 81 | 141 | 240 | 9,683 | |||||||||||||||
Operating
expenses
|
2,031 | 3,384 | 5,986 | 7,724 | 198,762 | |||||||||||||||
Interest expense on convertible
debentures
|
160 | 258 | 578 | 799 | 3,839 | |||||||||||||||
Accretion in carrying value of
convertible debentures
|
407 | 320 | 1,175 | 925 | 4,371 | |||||||||||||||
Amortization of deferred financing
charges
|
- | - | - | - | 412 | |||||||||||||||
Interest
income
|
(65 | ) | (120 | ) | (218 | ) | (435 | ) | (12,184 | ) | ||||||||||
Loss from operation for the
period
|
2,469 | 3,839 | 7,415 | 8,983 | 194,238 | |||||||||||||||
Gain on sale of shares (note 1
(b))
|
- | 11 | (450 | ) | (6,299 | ) | (6,749 | ) | ||||||||||||
Net loss and other comprehensive
loss for the period
|
2,469 | 3,850 | 6,965 | 2,684 | 187,489 | |||||||||||||||
Deficit, beginning of period as
previously reported
|
185,047 | 173,051 | 180,551 | 174,190 | - | |||||||||||||||
Change in accounting
policy
|
- | - | - | 27 | 27 | |||||||||||||||
Deficit, beginning of period as
revised
|
185,047 | 173,051 | 180,551 | 174,217 | ||||||||||||||||
Deficit, end of
period
|
$ | 187,516 | $ | 176,901 | $ | 187,516 | $ | 176,901 | $ | 187,516 | ||||||||||
Basic and diluted loss per common
share
|
$ | 0.01 | $ | 0.02 | $ | 0.03 | $ | 0.01 | ||||||||||||
Weighted average number of common
shares
|
||||||||||||||||||||
outstanding
used in the calculation of
|
||||||||||||||||||||
Basic
and diluted loss per share
|
253,538 | 215,751 | 244,039 | 214,386 | ||||||||||||||||
See accompanying notes to the
unaudited interim consolidated financial statements
|
Lorus Therapeutics
Inc.
|
||||||||||||||||||||
Interim Consolidated Statements of
Cash Flows (unaudited)
|
||||||||||||||||||||
Period
|
||||||||||||||||||||
Three
|
Three
|
Nine
|
Nine
|
from
inception
|
||||||||||||||||
(amounts in
000's)
|
months
ended
|
months
ended
|
months
ended
|
months
ended
|
Sept. 5, 1986
to
|
|||||||||||||||
(Canadian
Dollars)
|
Feb. 28,
2009
|
Feb. 29,
2008
|
Feb. 28,
2009
|
Feb. 29,
2008
|
Feb. 28,
2009
|
|||||||||||||||
Cash flows from
operating activities:
|
||||||||||||||||||||
Earnings (loss)
for the period
|
$ | (2,469 | ) | (3,850 | ) | $ | (6,965 | ) | $ | (2,684 | ) | $ | (187,489 | ) | ||||||
Items not
involving cash:
|
||||||||||||||||||||
Gain
on sale of shares
|
- | 11 | (450 | ) | (6,299 | ) | (6,749 | ) | ||||||||||||
Stock-based
compensation
|
111 | 217 | 347 | 529 | 8,319 | |||||||||||||||
Interest
on convertible debentures
|
160 | 258 | 578 | 799 | 3,839 | |||||||||||||||
Accretion
in carrying value of convertible debentures
|
407 | 320 | 1,175 | 925 | 4,371 | |||||||||||||||
Amortization
of deferred financing charges
|
- | - | - | - | 412 | |||||||||||||||
Depreciation,
amortization and write-down of fixed assets
|
||||||||||||||||||||
and
acquired patents and licenses
|
55 | 81 | 141 | 240 | 22,244 | |||||||||||||||
Other
|
(9 | ) | 15 | (9 | ) | (4 | ) | 446 | ||||||||||||
Change in
non-cash operating working capital
|
(44 | ) | 362 | (477 | ) | (977 | ) | 11 | ||||||||||||
Cash used in operating
activities
|
(1,789 | ) | (2,586 | ) | (5,660 | ) | (7,471 | ) | (154,596 | ) | ||||||||||
Cash flows from financing
activities:
|
||||||||||||||||||||
Issuance of debentures, net of
issuance costs
|
- | - | - | - | 12,948 | |||||||||||||||
Issuance (Repurchase) of
warrants
|
- | - | 417 | (252 | ) | 37,570 | ||||||||||||||
Proceeds on sale of shares, net of
arrangement costs and guarantee (note 1)
|
- | (11 | ) | 450 | 7,561 | 6,749 | ||||||||||||||
Issuance of common shares, net of
issuance costs (note 5)
|
- | - | 2,790 | - | 111,815 | |||||||||||||||
Additions to deferred
financing/arrangement charges
|
- | - | - | - | ||||||||||||||||
Cash provided by financing
activities
|
- | (11 | ) | 3,657 | 7,309 | 169,082 | ||||||||||||||
Cash flows from investing
activities:
|
||||||||||||||||||||
Maturity
(purchase) of marketable securities and other investments,
net
|
1,566 | 1,071 | 5,162 | 2,208 | (1,642 | ) | ||||||||||||||
Business
acquisition, net of cash received
|
- | - | - | (539 | ) | |||||||||||||||
Acquired patents
and licenses
|
- | - | - | - | (715 | ) | ||||||||||||||
Additions to
fixed assets
|
(163 | ) | (13 | ) | (167 | ) | (52 | ) | (6,294 | ) | ||||||||||
Proceeds on sale
of fixed assets
|
- | - | - | 348 | ||||||||||||||||
Cash (used in) provided by
investing activities
|
1,403 | 1,058 | 4,995 | 2,156 | (8,842 | ) | ||||||||||||||
Increase (decrease) in cash and
cash equivalents during the period
|
(386 | ) | (1,539 | ) | 2,992 | 1,994 | 5,644 | |||||||||||||
Cash and cash equivalents,
beginning of period
|
6,030 | 4,938 | 2,652 | 1,405 | - | |||||||||||||||
Cash and cash equivalents,
end of period
|
$ | 5,644 | $ | 3,399 | $ | 5,644 | $ | 3,399 | $ | 5,644 | ||||||||||
See accompanying notes to the
unaudited consolidated interim financial statements
|
1.
|
Basis of
presentation
|
2.
|
Changes
in Accounting policy
|
(i) | management is required to make an assessment of an entity’s ability to continue as a going concern; | |
|
(ii) |
in
making its assessment, management takes into account all available
information about the future, which is at least, but is not limited to,
twelve months from the balance sheet
date;
|
(iii) |
financial
statements must be prepared on a going concern basis unless management
either intends to liquidate the entity, to cease trading or cease
operations, or has no realistic alternative but to do
so;
|
|
(iv) |
disclosure
is required of material uncertainties related to events or conditions that
may cast significant doubt upon the entity’s ability to continue as a
going concern; and
|
|
(v) |
when financial statements are
not prepared on a going concern basis, that fact should be disclosed,
together with the basis on which the financial statements are prepared and
the reason the entity is not regarded as a going
concern.
|
3.
|
Capital
Risk Management
|
|
•
|
Maintain its ability to continue
as a going concern in order to provide returns to shareholders and
benefits to other
stakeholders;
|
|
•
|
Maintain a flexible capital
structure which optimizes the cost of capital at acceptable
risk;
|
|
•
|
Ensure sufficient cash resources
to fund its research and development activity, to pursue partnership and
collaboration opportunities and to maintain ongoing
operations.
|
4.
|
Financial
Instruments
|
February 28,
2009
|
May 31,
2008
|
|||||||
Financial
assets
|
||||||||
Cash
and cash equivalents, consisting of term
deposits,
|
||||||||
and
guaranteed investment certificates, held for
trading,
|
||||||||
measured at
fair value
|
$ | 5,644 | $ | 2,652 | ||||
Short-term
investments, held-to-maturity,
|
||||||||
recorded at
amortized cost
|
1,142 | 6,304 | ||||||
Short-term
investments, held-for-trading,
|
||||||||
recorded at
fair value
|
486 | 480 | ||||||
Amount
held in escrow, measured at amortized cost
|
- | 600 | ||||||
Financial
liabilities
|
||||||||
Accounts
payable, measured at amortized cost
|
312 | 923 | ||||||
Accrued
liabilities, measured at amortized cost
|
1,300 | 1,194 | ||||||
Secured
convertible debentures,
|
||||||||
measured at
amortized cost
|
13,915 | 12,742 | ||||||
5.
|
Share
capital
|
(amounts and
units in 000's)
|
Common
Shares
|
Warrants
|
||||||||||||||
Number
|
Amount | Number | Amount | |||||||||||||
Balance at May 31,
2007
|
212,266 | $ | 157,714 | - | $ | - | ||||||||||
Interest payments
(b)
|
1,227 | 270 | - | - | ||||||||||||
Balance at August 31,
2007
|
213,493 | $ | 157,984 | - | $ | - | ||||||||||
Interest payments
(b)
|
1,280 | 271 | - | - | ||||||||||||
Balance at November 30,
2007
|
214,773 | $ | 158,255 | - | $ | - | ||||||||||
Interest payments
(b)
|
1,452 | 258 | - | - | ||||||||||||
Balance at February 29,
2008
|
216,225 | $ | 158,513 | - | $ | - | ||||||||||
Interest payments
(b)
|
1,424 | 230 | - | - | ||||||||||||
Balance at May 31,
2008
|
217,649 | $ | 158,743 | - | $ | - | ||||||||||
Interest payments
(b)
|
2,038 | 217 | - | - | ||||||||||||
Issuance of units
(c)
|
28,539 | 2,790 | 14,269 | 417 | ||||||||||||
Balance at August 31,
2008
|
248,226 | $ | 161,750 | 14,269 | $ | 417 | ||||||||||
Interest payments
(b)
|
2,989 | 201 | - | - | ||||||||||||
Balance at November 30,
2008
|
251,215 | $ | 161,951 | 14,269 | $ | 417 | ||||||||||
Interest payments
(b)
|
3,406 | 160 | - | - | ||||||||||||
Balance at February 28,
2009
|
254,621 | $ | 162,111 | 14,269 | $ | 417 |
(b)
|
Interest
payments
|
Interest payments relate to interest payable on the $15.0 million convertible debentures payable at a rate of prime +1% until such time as the Company’s share price reaches $1.75 for 60 consecutive trading days, at which time, interest will no longer be charged. Common shares issued in payment of interest were issued at a price equal to the weighted average trading price of such shares for the ten trading days immediately preceding their issue in respect of each interest payment. |
(c)
|
Equity
issuances
|
(d)
|
Loss
per share
|
(e)
|
Continuity of
contributed surplus
|
Nine months
ended
|
Nine months
ended
|
|||||||
February 28,
2009
|
February 29,
2008
|
|||||||
Balance, beginning of
year
|
$ | 9,181 | $ | 8,525 | ||||
Forfeiture of stock
options
|
1,545 | 656 | ||||||
Balance, end of
period
|
$ | 10,726 | $ | 9,181 |
6.
|
Stock-based
compensation
|
Nine months
ended
|
Nine months
ended
|
|||||||||||||||
February 28,
2009
|
February 29,
2008
|
|||||||||||||||
Weighted
|
Weighted
|
|||||||||||||||
Average
|
average
|
|||||||||||||||
Options
|
exercise
|
Options
|
exercise
|
|||||||||||||
(in
thousands)
|
price
|
(in
thousands)
|
price
|
|||||||||||||
Outstanding,
|
||||||||||||||||
beginning of
year
|
16,438 | $ | 0.45 | 12,988 | $ | 0.59 | ||||||||||
Granted
|
5,124 | 0.10 | 6,048 | 0.21 | ||||||||||||
Exercised
|
- | - | - | - | ||||||||||||
Forfeited
|
(4,572 | ) | 0.67 | (1,848 | ) | 0.74 | ||||||||||
Outstanding,
|
||||||||||||||||
end of
period
|
16,990 | $ | 0.29 | 17,188 | $ | 0.44 |
Three months
ended
Feb 28,
2009
|
Nine months
ended
Feb 28,
2009
|
Three months
ended
Feb 29,
2008
|
Nine months
ended
Feb 29,
2008
|
|
Risk free interest
rate
|
Nil
|
2.0-4.75%
|
3.75-4.00%
|
3.75-4.00%
|
Expected
dividend yield
Expected
volatility
Expected
life of options
Weighted
average fair value of options granted or modified in the
period
|
Nil
Nil
Nil
Nil |
0%
80%
5 years
$0.07 |
0%
77%
5 years
$0.13 |
0%
77-80%
5 years
$0.14 |
(amounts in
000's)
|
2009 | 2008 | ||||||
Balance at beginning of the
year
|
$ | 4,961 | $ | 4,898 | ||||
Forfeiture of
vested stock options
|
- | (18 | ) | |||||
Stock option
expense
|
91 | 103 | ||||||
Balance at August
31,
|
$ | 5,052 | $ | 4,983 | ||||
Stock option
expense
|
145 | 209 | ||||||
Forfeiture of
vested stock options
|
(1,086 | ) | (587 | ) | ||||
Balance at November
30,
|
$ | 4,111 | $ | 4,605 | ||||
Forfeiture of
vested stock options
|
(459 | ) | (51 | ) | ||||
Stock option
expense
|
111 | 217 | ||||||
Balance at February
28,
|
$ | 3,763 | $ | 4,771 |
8.
|
Secured
convertible
debentures
|
9.
|
Related
party
transaction
|
10.
|
Indemnification
on Arrangement
|
|
(i)
|
prior
to, at or after the effective time of the Arrangement ("Effective Time")
and directly or indirectly relating to any of the assets of Old Lorus
transferred to New Lorus pursuant to the Arrangement (including losses for
income, sales, excise and other taxes arising in connection with the
transfer of any such asset) or conduct of the business prior to the
Effective Time;
|
|
(ii)
|
prior
to, at or after the Effective Time as a result of any and all interests,
rights, liabilities and other matters relating to the assets transferred
by Old Lorus to New Lorus pursuant to the Arrangement;
and
|
|
(iii)
|
prior
to or at the Effective Time and directly or indirectly relating to, with
certain exceptions, any of the activities of Old Lorus or the
Arrangement.
|
11.
|
Revenue
|